Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2016-11-18 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2016-11-18 English
10-Q
Interim / Quarterly Report Q3 2016
2016-11-15 English
10-Q/A
Interim / Quarterly Report Q2 2016
2016-11-15 English
10-Q/A
Interim / Quarterly Report Q1 2016
2016-11-15 English
10-K/A
Annual Report FY 2015
2016-11-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes detailed restatement of previously issued financial statements due to errors in deferred tax assets and convertible notes classification. It references prior earnings releases and corrections to GAAP net income and earnings per share. The document also discusses internal control weaknesses and the need to restate financials for specific periods. The presence of detailed financial adjustments and restatement information indicates this is not a simple earnings release or announcement but a regulatory filing reporting material corrections and financial restatements. The document is not a full annual or quarterly report but a current report on Form 8-K with financial restatement information. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like Earnings Release or Annual Report.
2016-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.